Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury
© Buss et al; licensee BioMed Central Ltd. 2007
Received: 16 March 2007
Accepted: 26 June 2007
Published: 26 June 2007
Matrix metalloproteinases (MMPs) are a family of extracellular endopeptidases that degrade the extracellular matrix and other extracellular proteins. Studies in experimental animals demonstrate that MMPs play a number of roles in the detrimental as well as in the beneficial events after spinal cord injury (SCI). In the present correlative investigation, the expression pattern of several MMPs and their inhibitors has been investigated in the human spinal cord.
An immunohistochemical investigation in post mortem samples of control and lesioned human spinal cords was performed. All patients with traumatic SCI had been clinically diagnosed as having "complete" injuries and presented lesions of the maceration type.
In the unlesioned human spinal cord, MMP and TIMP immunoreactivity was scarce. After traumatic SCI, a lesion-induced bi-phasic pattern of raised MMP-1 levels could be found with an early up-regulation in macrophages within the lesion epicentre and a later induction in peri-lesional activated astrocytes. There was an early and brief induction of MMP-2 at the lesion core in macrophages. MMP-9 and -12 expression peaked at 24 days after injury and both molecules were mostly expressed in macrophages at the lesion epicentre. Whereas MMP-9 levels rose progressively from 1 week to 3 weeks, there was an isolated peak of MMP-12 expression at 24 days. The post-traumatic distribution of the MMP inhibitors TIMP-1, -2 and -3 was limited. Only occasional TIMP immuno-positive macrophages could be detected at short survival times. The only clear induction was detected for TIMP-3 at survival times of 8 months and 1 year in peri-lesional activated astrocytes.
The involvement of MMP-1, -2, -9 and -12 has been demonstrated in the post-traumatic events after human SCI. With an expression pattern corresponding largely to prior experimental studies, they were mainly expressed during the first weeks after injury and were most likely involved in the destructive inflammatory events of protein breakdown and phagocytosis carried out by infiltrating neutrophils and macrophages, as well as being involved in enhanced permeability of the blood spinal cord barrier. Similar to animal investigations, the strong induction of MMPs was not accompanied by an expression of their inhibitors, allowing these proteins to exert their effects in the lesioned spinal cord.
After traumatic spinal cord injury (SCI), the initial damage to the parenchyma at the lesion site is followed by a complex cascade of secondary events including breakdown of the blood spinal cord barrier (BSB) and infiltration of blood-derived inflammatory cells, oedema, excitotoxicity and ischemia. Experimental investigations have revealed that this phase of secondary parenchymal damage spans the first 48–72 hours post injury and is followed by the removal of tissue debris over subsequent weeks. Finally, the lesion site of severely injured tissue becomes dominated by scar tissue comprised of connective tissue, including Schwann cells and meningeal fibroblasts, and fluid-filled cysts, surrounded by a dense astroglial scar . Remodelling of the extracellular matrix (ECM) plays an important role in most of these events
Matrix metalloproteinases (MMPs) are a family of extracellular zinc- and calcium-dependent endopeptidases that degrade the extracellular matrix and other extracellular proteins . The 23 mammalian MMPs can be placed into sub-groups based on structural similarities and substrate specificity and they are capable of degrading virtually all extracellular proteins. Once activated, MMPs are subject to inhibition by 4 different tissue inhibitors of metalloproteinases (TIMPs) that bind MMPs non-covalently . MMPs are involved in events requiring matrix remodelling in developmental processes, wound healing and repair throughout life. In the nervous system, these enzymes play a role in the migration of precursor cells to their destination and are directly involved in axonal outgrowth during development . However, the aberrant expression of members of this protein family is involved in disease processes such as cancer metastasis and CNS disorders including multiple sclerosis, stroke, Alzheimer's disease and trauma [4, 5]. Recent experimental SCI investigations have demonstrated an involvement of MMPs in the post-traumatic events. In a mouse spinal cord compression injury model, a significant up-regulation of 11 MMPs was demonstrated . Most of the proteins, including MMP-3, -9 and -10, showed an early induction, starting 24 hours after injury whereas the expression of other MMPs, including MMP-2, -12 and -13, was delayed until 5 days after trauma. Further studies into the role of MMP-12, the most markedly up-regulated MMP, demonstrated improved recovery in MMP-12 null mice, most likely due to a reduction of the lesion-induced permeability of the blood spinal cord barrier (BSB) and a reduced density of microglia/macrophages at the lesion site . An investigation into the role of MMP-9 in SCI showed similar results in a contusion injury model, with improved locomotor function in MMP-9 null mice as compared to wild-type animals. Again, a reduction of the lesion-induced permeability of the BSB and a resulting attenuation of inflammatory cell infiltration were suggested to be the likely mechanisms for the favourable outcome . Another study in mice undergoing a spinal cord contusion injury correlated the up-regulation of MMP-2 mainly to the formation of the glial scar . In MMP-2 null mice, there was reduced white matter sparing, less nerve fibre regeneration and a more extensive astroglial scarring compared to their wild type littermates. These results suggest that MMP-2 up-regulation promotes functional recovery after SCI by regulating glial scar formation and white matter sparing.
Therefore, studies in experimental animals have demonstrated that MMPs play a number of roles in the detrimental, early inflammation-related processes as well as in the later, beneficial wound healing and regenerative events [4, 5]. In the present investigation, the expression pattern of several MMPs and their inhibitors has been investigated in samples of post mortem human spinal cord, taken from 15 patients who died at a range of survival times following traumatic SCI. Our data reveals an induction of MMPs-1, -2, -9 and -12 with an individual profile for each protein. The present data demonstrates a strong correlation with some aspects of the data obtained from experimental animals. However, some clear differences appear to exist between animal and human tissues following spinal cord injury.
Patients who served as the control group
Cause of death
Patients who died after traumatic injury to the spinal cord
Transverse sections (5 μm thick) were collected onto poly-L-lysine-coated slides and allowed to dry. Sections were de-waxed in xylene and rehydrated. Microwave treatment in 10 mM citrate buffer (pH 6) for 3 × 3 minutes was followed by blockade of non-specific binding by incubation in 0.1 M PBS containing either 3% normal horse or normal goat serum and 0.5% triton X-100 for 30 minutes. Sections were subsequently incubated in the following primary antibodies, overnight at room temperature: mouse monoclonal anti-MMP-1 (1:4000; Chemicon), mouse monoclonal anti-MMP-2 (1:20; Calbiochem), mouse monoclonal anti-MMP-9 (1:100; R&D Systems), mouse monoclonal anti-MMP-12 (1:10; R&D Systems), mouse monoclonal anti-TIMP-1 (1:300; Chemicon), rabbit polyclonal anti-TIMP-2 (1:250; Chemicon), mouse monoclonal anti-TIMP-3 (1:100; Chemicon), rabbit polyclonal anti-glial fibrillary acidic protein (1:2500, DAKO) and mouse monoclonal anti-CD68 (1:50; DAKO). Following extensive rinsing steps in 0.1 M PBS, sections were incubated in biotinylated horse anti-mouse or goat anti-rabbit antibody (diluted 1:500, Vector Laboratories) for 1 hour at room temperature. Incubation with the biotinylated secondary antibody was followed by the Vector ABC system and a subsequent incubation in diaminobenzidine for visualization of the reaction product. For negative controls the primary antibody was omitted. Those sections incubated with the CD68 antibody were finally counterstained with 0.2% thionin for 1 minute.
Sections were de-waxed in xylene and rehydrated. Microwave treatment in 10 mM citrate buffer (pH 6) for 3 × 3 minutes was followed by blockade of non-specific binding by incubation in 3% normal goat serum in 0.5% triton X-100 in 0.1 M PBS for 30 minutes and subsequent incubation overnight at room temperature with the anti-MMP-1 antibody (1:250) or the anti-TIMP-3 antibody (1:20) and the anti-GFAP antibody (1:200). Following incubation with Alexa 594 (red-fluorescence)-conjugated goat anti-mouse and Alexa 488 (green fluorescence)-conjugated goat anti-rabbit secondary antibodies (diluted 1:500, Molecular Probes) for 3 hours at room temperature, slides were cover-slipped in Moviol.
For MMP and CD68 double staining, the tyramide signal amplification kit (TSA Cyanine 3 system, NEL704A, PerkinElmer Life Sciences) was used. Briefly, following the blockade of endogenous tissue peroxidase, sections were rinsed in the TSA block buffer (prepared as recommended by the manufacturers) and incubated with the anti-MMP-1, -2, -9 or -12 antibodies at a dilution of 1:200 overnight. Incubation with a biotinylated horse anti-mouse antibody (1:500, BA2000, Vector) for 1 hour, rinsing in 0.05% Tween20 and blocking with the provided reagent for 30 minutes was followed by streptavidin-HRP (1:500) in blocking reagent for 30 minutes and Cyanine 3-tyramide working solution (1:100) for 10 minutes. After rinsing, the slides were incubated with the monoclonal anti-CD68 primary antibody (1:30) overnight, followed by a Cy2-conjugated goat anti-mouse antibody (1:100, Jackson Laboratories) for 3 hours at room temperature. Finally, nuclei were stained for 5 minutes with DAPI (diluted 1:1000, Sigma) and the sections were cover-slipped with Moviol. For negative controls, the primary antibodies were omitted.
For a semi-quantitative description of the amount of MMP-immunoreactive cells at the various survival times, an arbitrary rating scale for the number of labelled cells was chosen, ranging from 0 to ++++. A value of 0 indicated the detection of no immunopositive cells while a value of ++++ indicated the presence of large numbers of labelled cells.
Amount of immunopositive cells at the lesion epicentre at different survival times following human SCI
Normal distribution of MMPs and TIMPs in the human spinal cord
Macrophage/microglial responses to human SCI
Astrocytic reaction to human SCI
Expression of MMP-1 after human SCI
Expression of MMP-2 after human SCI
Expression of MMP-9 after human SCI
By 2 days after injury (the earliest time point investigated) staining for MMP-9 demonstrated immunoreactive cells at and around the lesion site. In areas of severe tissue destruction and intensive bleeding, only few cells with a round morphology were stained (Fig.5E). At 4–5 days after injury, in areas at the lesion epicentre but without signs of hemorrhagic infiltration, the amount of immunoreactive cells was higher compared to other heavily destroyed areas. The cells were mostly of a round morphology and were relatively evenly distributed except for clusters of positive cells in and around blood vessels (Fig.5F). Double immunofluorescence with an anti-CD68 antibody demonstrated a microglia/macrophage origin of most MMP-9 positive cells (Fig.7D). Morphologically, the MMP-9 positive/CD68-negative cells at these early survival times resembled infiltrating neutrophils. In sections further away from the lesion, the number of immunoreactive cells decreased rapidly; such that hardly any MMP-9 positive cell could be detected one segment distal or proximal of the site of injury (Fig.5G). This distribution remained more or less constant up to 11 day post injury. By 24 days, large numbers of MMP-9 positive round cells were visible at the lesion core and filled the area of tissue destruction (Fig.5H). Double immunofluorescence revealed these cells to be phagocytosing macrophages (Fig.7E). At survival times of 4 months and later, only single MMP-9 immunoreactive cells were detectable at and around the lesion site, showing a distribution similar to that of control cases (not shown). Apart from microglia/macrophages and some neutrophils, no other cell population demonstrated immunoreactivity for MMP-9 at all time points (not shown).
Expression of MMP-12 after human SCI
In contrast to the other MMPs investigated, immunohistochemistry for MMP-12 only displayed rare immunopositive, rounded cells at and around the lesion site up to 11 days post injury (Fig.5I). This distribution changed dramatically by 24 days, when many intensely immunoreactive microglia/macrophages could be detected at the lesion core (Fig.5J and 7F). The number of stained cells decreased rapidly in sections further away from the lesion such that by 1 segment proximal and distal no immunoreactive cells were visible. In all cases with longer survival times, no specific MMP-12 staining was seen at and around the lesion site (not shown).
Expression of TIMP-1, -2 and -3 after human SCI
Immunohistochemistry for TIMP-2 demonstrated a temporal loss of neuronal staining. Immunoreactivity could be detected in most motoneurons and some interneurons for up to 4 days (Fig.6C). However, at survival times ranging from 8 to 24 days only single immunoreactive neurons were visible. This was particularly evident for TIMP-2 staining in motoneurons close to the lesion site (Fig.6D). From 4 months, the remaining neurons displayed a staining pattern comparable to the control cases with most distinguishable motoneurons being TIMP-2 positive and some positive interneurons in laminae I to VI (not shown). Apart from intermittent immunopositive macrophages and stained neurons, no other cell population demonstrated TIMP-2 immunoreactivity. In contrast to TIMP-2, the neuronal staining pattern of TIMP-3 remained unchanged over the range of survival times. About half of the motoneurons were stained and single interneurons could always be seen at and around the site of injury (Fig.6E and 6G). Activated astrocytes became transiently immunopositive for TIMP-3 between 8 months to 1 year after SCI (Fig.6H and 7G). Survival times of greater than 1 year only revealed neuronal TIMP-3 immunoreactivity (not shown).
MMPs in the CNS are largely synthesized by endothelial cells, microglia, astrocytes and neurons under normal conditions and can be produced at elevated levels in response to stress . A number of reports have indicated that MMPs are involved in the pathogenesis of a wide range of diseases and disorders of the CNS, including neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease and progressive supranuclear cerebral palsy [10–14] as well as stroke injuries . It has been suggested that this class of extracellular proteases may be appropriate molecular targets to reduce secondary tissue degeneration and improve functional outcome [7, 16]. Although recent studies have demonstrated the involvement of MMPs in experimental models of spinal cord injury, there has, until now, been only one recent correlative investigation regarding the spatio-temporal distribution of MMP-9 in human spinal cord injury . In the present study, the timing and distribution of MMP-1, -2, -9 and -12, as well as their tissue inhibitors TIMP-1, -2 and -3 were investigated in both normal and traumatically injured samples of human spinal cord. In an attempt to obtain tissue samples that were as comparable as possible, an emphasis has been placed on using samples obtained from cases which underwent similar lesion type and severity. Therefore, all patients with traumatic SCI suffered severe injuries of the maceration type (for a detailed description of the morphology of the lesion sites, see ) and were clinically diagnosed as having "complete" injuries. The paucity of human specimens led to the inclusion of cases from different age groups and varying levels of injury. Thus, the present data needs to be interpreted with care and can, by no means, be easily generalised to patients suffering from other types or severities of SCI. Thus, it is clear that future studies will be needed to verify if a similar pattern of post-traumatic MMP and TIMP expression at the lesion site can be found in less severe- as well as other types of SCI (e.g. following laceration and contusion type injuries). The comparison of the present data with previous results demonstrated that the spatio-temporal pattern of microglia/macrophages and astrocytic responses (i.e. the main cell populations demonstrating post traumatic MMP immunoreactivity in the present study) supports earlier investigations in human SCI .
Expression of MMPs and TIMPs in the normal CNS
In the normal, unlesioned human brain and spinal cord, MMP and TIMP immunoreactivity was generally scarce. The data obtained from prior investigations on the expression of MMP-1, -2 and -9 in the human nervous system have been inconsistent, reporting either no immunoreactivity [17, 19–21] or MMP-1 positive microglia , MMP-2 positive microglia, pericytes and blood vessels [7, 14, 22, 23], MMP-9 immunoreactive neurons, microglia and single intravascular monocytes [10, 22, 23] and MMP-12 immunoreactive microglia and astrocytes . No immunoreactivity for TIMP-1 and -3 has been detected. However, TIMP-2 has been found in endothelial cells and occasional neurons and astrocytes .
In the present investigation, neuronal staining for MMP-1, TIMP-2 and -3 was detected as well as individual MMP-9 positive intravascular monocytes. In general, the inevitable delays that occur before human post mortem tissues undergo fixation will result in sub-optimal antigen preservation. It therefore always remains possible that low levels of antigen, below the level of detection by the current immunohistochemical approach, may still be present at pathophysiologically relevant concentrations. All molecules were, nonetheless, clearly detectable in either both control or pathological cases.
Whereas the pattern of MMP-9 immunoreactivity observed in the present investigation supports pervious data , the neuronal expression of MMP-1 has, so far, not been reported. The expression of TIMP-2 and -3 in different populations of neurons, though not previously described in human material, is in line with animal data where both inhibitors were detected in cortical and cerebellar neurons .
The lack of immunoreactivity for MMP-2, -12 and TIMP-1 in the present control cases is unlikely to be attributable to a lack of sensitivity, since a clear signal could be detected in sections of traumatically injured spinal cord. It is possible, however remote, that the earlier described immunoreactivity in astrocytes, microglia and blood vessels may reflect more activated populations of cells in the previous control cases, despite the lack of morphological signs of disease. In contrast to an extensive literature on the function of MMPs and their inhibitors in pathological situations, there is hardly any information on their function under normal conditions apart from those instances where they have been associated with plasticity .
Expression of MMPs and TIMPs following human spinal cord injury
In the present investigation, a post-traumatic up-regulation of MMP-1, -2, -9 and -12 was detected. Following experimental SCI, several studies have reported the involvement of various MMPs and TIMPs in the post-traumatic events at and around the lesion site. In particular, the temporal expression pattern of almost all MMPs has been studied after compression injury to the mouse spinal cord . An up-regulation of multiple MMPs, including MMP-2, -9 and -12 was detected, which occurred in a time-dependent manner, i.e. an early elevation of one group of proteins including MMP-9 and a more delayed elevation of others including MMP-2 and -12. In contrast to the present investigation, MMP-1 could not be detected in mouse spinal cord samples, at least up to 5 days after injury .
The present post mortem investigation of human material revealed a lesion-induced bi-phasic pattern of raised MMP-1 levels at and around the lesion site. At survival times of up to 8 days, MMP-1 was expressed in macrophages and microglia within the lesion epicentre, however, at the later survival times of 4 months to 1 year, activated astrocytes at the border of the glial scar became strongly MMP-1 immunoreactive. The delayed up-regulation of MMP-1 in astrocytes in the spinal cord parenchyma around the lesion site might be a consequence of earlier pro-inflammatory cytokine production since in vitro investigations have demonstrated the release of MMP-1 from astrocytes when stimulated by TNF-alpha or IL-1β . Furthermore, cytokines regulate the activity of both gelatinases A and B (MMP-2 and -9) in cultured rat astrocytes [25, 26]. The early induction of MMP-1 in the present investigation may have been associated with the further pathological breakdown of the blood-spinal cord barrier (see later), however, the role of the later induction MMP-1 in reactive astroglia expression is less clear. Experimental studies on wound repair after skin lesions have demonstrated an increased expression of MMPs, including MMP-1 in the scarless healing process of fetal injuries [27, 28]. Furthermore, an investigation into regeneration-associated factors in the adult rat optic nerve revealed an increased post-traumatic expression of MMP-1 in peri-lesional astrocytes . Therefore, it might be possible that the presence of MMP-1 in the population of peri-lesional astrocytes at the border of the evolving glial scar, might play a role in limiting the extension of this residual tissue barrier.
Several reports have demonstrated post-traumatic and post-ischaemic increases in MMP-2 [6, 30–32]. Increased MMP-2 signals were detected at both protein and mRNA levels, with elevated expression levels lasting several weeks following experimental rat spinal cord injury . A recent investigation using MMP-2 knock-out mice demonstrated a more severe outcome following traumatic SCI in mice lacking MMP-2 . Knock-out mice demonstrated a reduced white matter sparing, a more widespread reactive astrogliosis as well as an impairment in spontaneous locomotor recovery compared to wild-type littermates. In the wild-type animals undergoing SCI, MMP-2 was mainly expressed in astrocytes and some macrophages for up to 2 weeks at the borders of the lesion site. In the present human material, there was an early and brief induction of MMP-2 in macrophages and microglia which lasted from 2 to 8 days after injury. By 24 days, when the first clear morphological indication of scar formation was visible, MMP-2 expression was on the borderline of detectability. In contrast to the situation in experimental animals, it is likely that MMP-2 expression after human traumatic SCI is more involved with the early vascular and inflammatory events than with reactive astrocytosis. In contrast to SCI, previous studies using post mortem human tissue of multi-infarct induced dementia, ALS and Parkinson's disease demonstrated the expression of MMP-2 at the border of the evolving astroglial scar or in astroglia in the cerebral cortex or substantia nigra [12, 13, 30]. The cellular distribution of MMP-2 expression in human pathology therefore appears to differ significantly in relation to the particular disease or disorder under investigation.
Contused mouse spinal cord demonstrated substantial blood vessel wall and astrocytic MMP-9 immunoreactivity within 3 days of injury . Furthermore, the use of MMP-9 knock-out mice following SCI demonstrated a favourable functional outcome compared to wild type animals, with reduced blood-spinal cord barrier permeability after the lesion and increased spared white matter . In the present study of severe traumatic SCI of the maceration type of injury, MMP-9 was mostly expressed in macrophages/microglia, where levels rose progressively from 1 week to 3 weeks after injury. However, some neutrophils were also found to be MMP-9 immunopositive at survival times of up to 8 days after injury. Although delayed, this spatio-temporal expression pattern is similar to that observed in experimental investigations [6, 31, 32]. However, a recent investigation of human traumatic SCI, using a heterogeneous sample of patients, found an early increase in MMP-9 at the lesion site for up to 10 days after injury and showed neutrophils to be the only cellular source . One possible explanation for the differences observed between the present investigation and that of Fleming and colleagues may be the differences in severity and mechanism of injury for the cases chosen. Therefore, additional studies which assess the influence of different mechanisms of injury (e.g. maceration or laceration) on the spatio-temporal patterns of cellular invasion and protein expression would be useful. This is of particular importance when experimental strategies are transferred to the clinical domain.
The up-regulation of MMP-12 following human SCI was delayed for up to 24 days, at which time an abrupt increase in the number of immunoreactive microglia/macrophages could be detected. Macrophages have already been described as a principal source of MMP-12 . The use of PCR following experimental mouse SCI revealed that, of all MMPs induced following traumatic injury, the induction of MMP-12 was by far the most striking, being approximately 189-fold greater than the basal levels. Furthermore, the importance of MMP-12 expression was demonstrated by using knock-out mice, in which an improved functional outcome was observed following SCI. This beneficial effect was reported to be due to a reduced permeability of the blood-spinal cord barrier and hence reduced infiltration by neutrophils and macrophages, as well as a lack of direct MMP-12-induced toxicity .
In contrast to the MMPs investigated in the present study, the detection and distribution of their inhibitors TIMP-1, -2 and -3 was limited. Only occasional TIMP immuno-positive macrophages could be detected at survival times of 2 – 24 days post injury. Neuronal TIMP-2 immunoreactivity was qualitatively reduced in comparison to control cases. The imbalance between MMPs and their respective TIMPs in certain situations may contribute to the development of pathology. Such an imbalance has already been described following experimental SCI in mice and also in the cerebral cortex of patients suffering PSP [7, 14]. The minor up-regulation of TIMPs detected in the present study is largely in line with experimental studies using mice, in which a short term, transient up-regulation of TIMP-1 was detected following spinal cord compression injuries . Therefore, similar to animal investigations, the strong induction of multiple MMPs after human SCI was not accompanied by a concomitant expression of their inhibitors, allowing these proteins to exert their effects in the lesioned spinal cord. The only clear increase in TIMP immunoreactivity was detected for TIMP-3 at survival times of 8 months and 1 year. In sections from these cases, the same peri-lesional activated astrocytes which expressed MMP-1 were also immunoreactive for TIMP-3. It may be that the up-regulation of TIMP-3 acts to limit the effects of MMP-1, but this suggestion remains speculative.
The involvement of MMP-1, -2, -9 and -12 has been demonstrated in the post-traumatic events after human SCI. This investigation comprised of 15 patients who died at a range of different survival times after trauma. Due to the difficulties in obtaining post mortem human tissue specimens, only one case could be studied at each survival time. Although cases with similar survival times demonstrated similar immunohistochemical staining patterns, the present results need to be interpreted with caution, and further studies with more human cases per survival time would be of significant value.
All 4 MMPs were mainly expressed during the first weeks after injury and are most likely involved in the destructive inflammatory events of protein breakdown and phagocytosis by infiltrating neutrophils and macrophages as well as enhanced permeability of the blood-spinal cord barrier. Their temporal expression pattern corresponds largely to prior experimental studies, several of which have indicated that inhibition of MMPs may lead to improved functional outcomes. However, the lack of any clear indication of the exact functional role (beneficial or detrimental) of many MMPs in human spinal cord, plus the lack of specific inhibitors suggests that more research on this issue is warranted. Nonetheless, the present data on the spatio-temporal expression of MMPs and TIMPs following human SCI has demonstrated that experimental animal models do not always accurately predict the timing and expression pattern of key molecules in the clinical situation, and that such correlative investigations are important for the logical extension of drug development from the laboratory to the clinic.
Blood Spinal Cord barrier
Central nervous system
Glial fibrillary acidic protein
Spinal cord injury
Tissue inhibitors of metalloproteinases
The authors thank S. Lecouturier for excellent technical assistance. This work was supported by a grant from the Deutsche Stiftung Querschnittslähmung (DSQ).
- Schwab ME, Bartholdi D: Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev. 1996, 76: 319-70.PubMedGoogle Scholar
- Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001, 17: 463-516. 10.1146/annurev.cellbio.17.1.463.View ArticlePubMedPubMed CentralGoogle Scholar
- Dzwonek J, Rylski M, Kaczmarek L: Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett. 2004, 567: 129-35. 10.1016/j.febslet.2004.03.070.View ArticlePubMedGoogle Scholar
- Yong VW, Power C, Forsyth P, Edwards DR: Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001, 2: 502-11. 10.1038/35081571.View ArticlePubMedGoogle Scholar
- Yong VW: Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci. 2005, 6: 931-944. 10.1038/nrn1807.View ArticlePubMedGoogle Scholar
- Wells JE, Rice TK, Nuttall RK, Edwards DR, Zekki H, Rivest S, Yong VW: An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. J Neurosci. 2003, 23: 10107-15.PubMedGoogle Scholar
- Noble LJ, Donovan F, Igarashi T, Goussev S, Werb Z: Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci. 2002, 22: 7526-35.PubMedPubMed CentralGoogle Scholar
- Hsu JY, McKeon R, Goussev S, Werb Z, Lee JU, Trivedi A, Noble-Haeusslein LJ: Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J Neurosci. 2006, 26: 9841-9850. 10.1523/JNEUROSCI.1993-06.2006.View ArticlePubMedPubMed CentralGoogle Scholar
- Rosenberg GA: Matrix metalloproteinases in neuroinflammation. Glia. 2002, 39: 279-291. 10.1002/glia.10108.View ArticlePubMedGoogle Scholar
- Asahina M, Yoshiyama Y, Hattori T: Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol. 2001, 20: 60-63.PubMedGoogle Scholar
- Backstrom JR, Miller CA, Tokes ZA: Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J Neurochem. 1992, 58: 983-992. 10.1111/j.1471-4159.1992.tb09352.x.View ArticlePubMedGoogle Scholar
- Lim GP, Backstrom JR, Cullen MJ, Miller CA, Atkinson RD, Tokes ZA: Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J Neurochem. 1996, 67: 251-259.View ArticlePubMedGoogle Scholar
- Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF: Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol. 2002, 178: 13-20. 10.1006/exnr.2002.8019.View ArticlePubMedGoogle Scholar
- Lorenzl S, Albers DS, Chirichigno JW, Augood SJ, Beal MF: Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. J Neurol Sci. 2004, 218: 39-45. 10.1016/j.jns.2003.10.015.View ArticlePubMedGoogle Scholar
- Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR: Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997, 238: 53-56. 10.1016/S0304-3940(97)00859-8.View ArticlePubMedGoogle Scholar
- Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998, 29: 1020-1030.View ArticlePubMedGoogle Scholar
- Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE, Saenz AD, Pasquale-Styles M, Dietrich WD, Weaver LC: The cellular inflammatory response in human spinal cords after injury. Brain. 2006Google Scholar
- Buss A, Pech K, Kakulas BA, Martin D, Schoenen J, Noth J, Brook GA: Growth-modulating molecules are associated with invading Schwann cells and not astrocytes in human traumatic spinal cord injury. Brain. 2007, epub ahead of print:Google Scholar
- Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, van der Valk P, de Groot CJ: Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol (Berl). 1997, 94: 590-8. 10.1007/s004010050754.View ArticleGoogle Scholar
- Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B: Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol. 1998, 153: 429-37.View ArticlePubMedPubMed CentralGoogle Scholar
- Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, Okada Y: Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg. 1994, 81: 69-77.View ArticlePubMedGoogle Scholar
- Maeda A, Sobel RA: Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol. 1996, 55: 300-9.View ArticlePubMedGoogle Scholar
- Rosenberg GA, Sullivan N, Esiri MM: White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke. 2001, 32: 1162-8.View ArticlePubMedGoogle Scholar
- Vos CM, van Haastert ES, de Groot CJ, van der Valk P, de Vries HE: Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J Neuroimmunol. 2003, 138: 106-14. 10.1016/S0165-5728(03)00036-5.View ArticlePubMedGoogle Scholar
- Gottschall PE, Yu X: Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem. 1995, 64: 1513-1520.View ArticlePubMedGoogle Scholar
- Vos CM, Sjulson L, Nath A, McArthur JC, Pardo CA, Rothstein J, Conant K: Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp Neurol. 2000, 163: 324-330. 10.1006/exnr.2000.7388.View ArticlePubMedGoogle Scholar
- Dang CM, Beanes SR, Lee H, Zhang X, Soo C, Ting K: Scarless fetal wounds are associated with an increased matrix metalloproteinase-to-tissue-derived inhibitor of metalloproteinase ratio. Plast Reconstr Surg. 2003, 111: 2273-85. 10.1097/01.PRS.0000060102.57809.DA.View ArticlePubMedGoogle Scholar
- Peled ZM, Phelps ED, Updike DL, Chang J, Krummel TM, Howard EW, Longaker MT: Matrix metalloproteinases and the ontogeny of scarless repair: the other side of the wound healing balance. Plast Reconstr Surg. 2002, 110: 801-11. 10.1097/00006534-200209010-00013.View ArticlePubMedGoogle Scholar
- Ahmed Z, Dent RG, Leadbeater WE, Smith C, Berry M, Logan A: Matrix metalloproteases: degradation of the inhibitory environment of the transected optic nerve and the scar by regenerating axons. Mol Cell Neurosci. 2005, 28: 64-78. 10.1016/j.mcn.2004.08.013.View ArticlePubMedGoogle Scholar
- Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH: Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol. 1997, 23: 406-415. 10.1046/j.1365-2990.1997.00066.x.View ArticlePubMedGoogle Scholar
- de Castro RC, Burns CL, McAdoo DJ, Romanic AM: Metalloproteinase increases in the injured rat spinal cord. Neuroreport. 2000, 11: 3551-4. 10.1097/00001756-200011090-00029.View ArticlePubMedGoogle Scholar
- Duchossoy Y, Horvat JC, Stettler O: MMP-related gelatinase activity is strongly induced in scar tissue of injured adult spinal cord and forms pathways for ingrowing neurites. Mol Cell Neurosci. 2001, 17: 945-56. 10.1006/mcne.2001.0986.View ArticlePubMedGoogle Scholar
- Shapiro SD, Kobayashi DK, Ley TJ: Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem. 1993, 268: 23824-9.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/7/17/prepub